Helius Medical Technologies, Inc. Restates Audited Earnings Results for the Fiscal Year Ended March 31, 2015, for the Periods Ended June 30, 2015, June 30, 2014, Quarter and Six Months Ended September 30, 2015, and for the Quarter Ended September 30, 2014
January 11, 2016 at 08:56 am
Share
Helius Medical Technologies, Inc. restated audited earnings results for the fiscal year ended March 31, 2015, for the periods ended June 30, 2015, June 30, 2014, quarter and six months ended September 30, 2015, and for the quarter ended September 30, 2014. For the year ended March 31, 2015, the company restated net loss to $9,838,317 or $0.17 per basic and diluted share against $8,894,555 or $0.16 per basic and diluted share as originally reported.
For the period ended June 30, 2015, the company restated net loss to $2,511,781 or $0.04 per basic and diluted share against $3,094,854 or $0.05 per basic and diluted share as originally reported.
For the period ended June 30, 2014, the company restated net loss to $1,563,953 or $0.04 per basic and diluted share against $1,568,754 or $0.04 per basic and diluted share as originally reported.
For the quarter ended September 30, 2015, the company restated net income to $1,375,281 or $0.02 per basic and diluted share against $1,039,361 or $0.02 per basic and diluted share as originally reported.
For the six months ended September 30, 2015, the company restated net loss to $1,136,500 or $0.02 per basic and diluted share against $2,055,493 or $0.03 per basic and diluted share as originally reported.
For the quarter ended September 30, 2014, the company restated net loss to $3,756,127 or $0.06 per basic and diluted share against $3,347,223 or $0.05 per basic and diluted share as originally reported.
For the six months ended September 30, 2014, the company restated net income to $5,320,080 or $0.10 per basic and diluted share against $4,915,977 or $0.10 per basic and diluted share as originally reported.
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brainâs ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
Helius Medical Technologies, Inc. Restates Audited Earnings Results for the Fiscal Year Ended March 31, 2015, for the Periods Ended June 30, 2015, June 30, 2014, Quarter and Six Months Ended September 30, 2015, and for the Quarter Ended September 30, 2014
HELIUS MEDICAL TECHNOLOGIES, INC. 
